Skip to content

The effect of herbal mixture capsule on constipation and sexual function of postmenopausal women with chronic constipation

The effect of herbal mixture capsule on constipation and sexual function of postmenopausal women with chronic constipation

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016043010324N32
Enrollment
64
Registered
2016-08-14
Start date
2016-08-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Constipation. Condition 2: Sexual dysfunction. Constipation Sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: The intervention group will receive herbal mixture capsules (including Cloves, Anise, Fennel, Green Raisins, Manna, Violet, Yellow Hill, Senate and Gland) twice a day (before lunch and
Treatment - Drugs
The intervention group will receive herbal mixture capsules (including Cloves, Anise, Fennel, Green Raisins, Manna, Violet, Yellow Hill, Senate and Gland) twice a day (before lunch and before dinner)
The control group will receive placebo capsules containing wheat flour for two times a day (before lunch and before dinner) and each time two capsules.

Sponsors

Vice chancellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Postmenopausal women with chronic constipation according to the Rome 3 criteria; Ages between 40 and 60 years old; No allergy to herbal ingredients used in the study; Married women that are living with their partners; Having literacy for reading and writing; Having telephone number; Having willingness to participate in the study Exclusion criteria: Suffering from metabolic disease causing constipation (hypothyroidism, hyperparathyroidism and diabetes); Suffering from neuromuscular disease (multiple sclerosis, stroke, Parkinson); Suffering from diarrhea; use of medications such as opioids, antidepressants, calcium channel blockers, ibuprofen , anticonvulsants, diuretics and iron and calcium supplements; Suffering from digestive system diseases including colorectal cancer, inflammation and narrowing of the digestive system; Use of medications to relieve constipation for a week prior to the study, Hormone therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Chronic constipation. Timepoint: Every week. Method of measurement: Questionnaire based on Rome 3 criteria including sequence of bowel movements, stool consistency, straining during defecation, feeling of incomplete evacuation during defecation, feeling of blockage disposal and the need to manipulate to facilitate defecation.;Female sexual function. Timepoint: Before and four weeks after the intervention. Method of measurement: Female Sexual Function Index.

Secondary

MeasureTime frame
Constipation symptom. Timepoint: At the end of the second and fourth week after intervention. Method of measurement: Patient Assessment of Constipation Symptom Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParia Eliasvandi

Faculty of Nursing & Midwifery, Tabriz University of Medical Sciences

eliasvandi.p@gmail.com+98 83 4512 4286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026